Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. / Hellem, Marie N.N.; Cheong, Rachel Y.; Tonetto, Simone; Vinther-Jensen, Tua; Hendel, Rebecca K.; Larsen, Ida U.; Nielsen, Troels T.; Hjermind, Lena E.; Vogel, Asmus; Budtz-Jørgensen, Esben; Petersén, Åsa; Nielsen, Jørgen E.

I: Parkinsonism and Related Disorders, Bind 99, 2022, s. 23-29.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hellem, MNN, Cheong, RY, Tonetto, S, Vinther-Jensen, T, Hendel, RK, Larsen, IU, Nielsen, TT, Hjermind, LE, Vogel, A, Budtz-Jørgensen, E, Petersén, Å & Nielsen, JE 2022, 'Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients', Parkinsonism and Related Disorders, bind 99, s. 23-29. https://doi.org/10.1016/j.parkreldis.2022.05.003

APA

Hellem, M. N. N., Cheong, R. Y., Tonetto, S., Vinther-Jensen, T., Hendel, R. K., Larsen, I. U., Nielsen, T. T., Hjermind, L. E., Vogel, A., Budtz-Jørgensen, E., Petersén, Å., & Nielsen, J. E. (2022). Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. Parkinsonism and Related Disorders, 99, 23-29. https://doi.org/10.1016/j.parkreldis.2022.05.003

Vancouver

Hellem MNN, Cheong RY, Tonetto S, Vinther-Jensen T, Hendel RK, Larsen IU o.a. Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. Parkinsonism and Related Disorders. 2022;99:23-29. https://doi.org/10.1016/j.parkreldis.2022.05.003

Author

Hellem, Marie N.N. ; Cheong, Rachel Y. ; Tonetto, Simone ; Vinther-Jensen, Tua ; Hendel, Rebecca K. ; Larsen, Ida U. ; Nielsen, Troels T. ; Hjermind, Lena E. ; Vogel, Asmus ; Budtz-Jørgensen, Esben ; Petersén, Åsa ; Nielsen, Jørgen E. / Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. I: Parkinsonism and Related Disorders. 2022 ; Bind 99. s. 23-29.

Bibtex

@article{9831794e97934571832d934886d2069d,

title = "Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients",

abstract = "Objective: Huntington's disease (HD) is an inherited neurodegenerative disease with motor, cognitive and psychiatric symptoms. Non-motor symptoms like depression and altered social cognition are proposed to be caused by dysfunction of the hypothalamus. We measured the hypothalamic neuropeptide oxytocin in plasma and cerebrospinal fluid (CSF) in a cohort of HD gene expansion carriers (HDGECs), compared the levels to healthy HD family controls and correlated oxytocin levels to disease progression and social cognition. Methods: We recruited 113 HDGECs and 33 controls. Psychiatric and cognitive symptoms were evaluated, and social cognition was assessed with the Emotion Hexagon test, Reading the Mind in the Eyes and The Awareness of Social Inference Test. The levels of oxytocin in CSF and blood were analyzed by radioimmunoassay. Results: We found the level of oxytocin in CSF to be significantly lower by 33.5% in HDGECs compared to controls (p = 0.016). When dividing the HDGECs into groups with or without cognitive impairment, we found the oxytocin level to be significantly lower by 30.3% in the HDGECs with cognitive symptoms (p = 0.046). We found a statistically significant correlation between the level of oxytocin and scores on social cognition (Reading the Mind in the Eyes p = 0.0019; Emotion Hexagon test: p = 0.0062; The Awareness of Social Inference Test: p = 0.002). Conclusions: This is the first study to measure oxytocin in the CSF of HDGECs. We find that HDGECs have a significantly lower level of oxytocin compared to controls, and that the level of oxytocin may represent an objective and comparable measure that could be used as a state biomarker for impairment of social cognition. We suggest treatment trials to evaluate a potential effect of oxytocin on social cognition in HD.",

keywords = "Huntington's disease, Neuroendocrinology, Oxytocin, Social cognition",

author = "Hellem, {Marie N.N.} and Cheong, {Rachel Y.} and Simone Tonetto and Tua Vinther-Jensen and Hendel, {Rebecca K.} and Larsen, {Ida U.} and Nielsen, {Troels T.} and Hjermind, {Lena E.} and Asmus Vogel and Esben Budtz-J{\o}rgensen and {\AA}sa Peters{\'e}n and Nielsen, {J{\o}rgen E.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

doi = "10.1016/j.parkreldis.2022.05.003",

language = "English",

volume = "99",

pages = "23--29",

journal = "Parkinsonism & Related Disorders",

issn = "1353-8020",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients

AU - Hellem, Marie N.N.

AU - Cheong, Rachel Y.

AU - Tonetto, Simone

AU - Vinther-Jensen, Tua

AU - Hendel, Rebecca K.

AU - Larsen, Ida U.

AU - Nielsen, Troels T.

AU - Hjermind, Lena E.

AU - Vogel, Asmus

AU - Budtz-Jørgensen, Esben

AU - Petersén, Åsa

AU - Nielsen, Jørgen E.

PY - 2022

Y1 - 2022

N2 - Objective: Huntington's disease (HD) is an inherited neurodegenerative disease with motor, cognitive and psychiatric symptoms. Non-motor symptoms like depression and altered social cognition are proposed to be caused by dysfunction of the hypothalamus. We measured the hypothalamic neuropeptide oxytocin in plasma and cerebrospinal fluid (CSF) in a cohort of HD gene expansion carriers (HDGECs), compared the levels to healthy HD family controls and correlated oxytocin levels to disease progression and social cognition. Methods: We recruited 113 HDGECs and 33 controls. Psychiatric and cognitive symptoms were evaluated, and social cognition was assessed with the Emotion Hexagon test, Reading the Mind in the Eyes and The Awareness of Social Inference Test. The levels of oxytocin in CSF and blood were analyzed by radioimmunoassay. Results: We found the level of oxytocin in CSF to be significantly lower by 33.5% in HDGECs compared to controls (p = 0.016). When dividing the HDGECs into groups with or without cognitive impairment, we found the oxytocin level to be significantly lower by 30.3% in the HDGECs with cognitive symptoms (p = 0.046). We found a statistically significant correlation between the level of oxytocin and scores on social cognition (Reading the Mind in the Eyes p = 0.0019; Emotion Hexagon test: p = 0.0062; The Awareness of Social Inference Test: p = 0.002). Conclusions: This is the first study to measure oxytocin in the CSF of HDGECs. We find that HDGECs have a significantly lower level of oxytocin compared to controls, and that the level of oxytocin may represent an objective and comparable measure that could be used as a state biomarker for impairment of social cognition. We suggest treatment trials to evaluate a potential effect of oxytocin on social cognition in HD.

AB - Objective: Huntington's disease (HD) is an inherited neurodegenerative disease with motor, cognitive and psychiatric symptoms. Non-motor symptoms like depression and altered social cognition are proposed to be caused by dysfunction of the hypothalamus. We measured the hypothalamic neuropeptide oxytocin in plasma and cerebrospinal fluid (CSF) in a cohort of HD gene expansion carriers (HDGECs), compared the levels to healthy HD family controls and correlated oxytocin levels to disease progression and social cognition. Methods: We recruited 113 HDGECs and 33 controls. Psychiatric and cognitive symptoms were evaluated, and social cognition was assessed with the Emotion Hexagon test, Reading the Mind in the Eyes and The Awareness of Social Inference Test. The levels of oxytocin in CSF and blood were analyzed by radioimmunoassay. Results: We found the level of oxytocin in CSF to be significantly lower by 33.5% in HDGECs compared to controls (p = 0.016). When dividing the HDGECs into groups with or without cognitive impairment, we found the oxytocin level to be significantly lower by 30.3% in the HDGECs with cognitive symptoms (p = 0.046). We found a statistically significant correlation between the level of oxytocin and scores on social cognition (Reading the Mind in the Eyes p = 0.0019; Emotion Hexagon test: p = 0.0062; The Awareness of Social Inference Test: p = 0.002). Conclusions: This is the first study to measure oxytocin in the CSF of HDGECs. We find that HDGECs have a significantly lower level of oxytocin compared to controls, and that the level of oxytocin may represent an objective and comparable measure that could be used as a state biomarker for impairment of social cognition. We suggest treatment trials to evaluate a potential effect of oxytocin on social cognition in HD.

KW - Huntington's disease

KW - Neuroendocrinology

KW - Oxytocin

KW - Social cognition

U2 - 10.1016/j.parkreldis.2022.05.003

DO - 10.1016/j.parkreldis.2022.05.003

M3 - Journal article

C2 - 35580426

AN - SCOPUS:85130334629

VL - 99

SP - 23

EP - 29

JO - Parkinsonism & Related Disorders

JF - Parkinsonism & Related Disorders

SN - 1353-8020

ER -

ID: 308890946